Cargando…
The potential benefits of low-molecular-weight heparins in cancer patients
Cancer patients are at increased risk of venous thromboembolism due to a range of factors directly related to their disease and its treatment. Given the high incidence of post-surgical venous thromboembolism in cancer patients and the poor outcomes associated with its development, thromboprophylaxis...
Autor principal: | Robert, Francisco |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2830957/ https://www.ncbi.nlm.nih.gov/pubmed/20074349 http://dx.doi.org/10.1186/1756-8722-3-3 |
Ejemplares similares
-
Low molecular weight heparin in COVID-19: benefits and concerns
por: Makarem, Adham, et al.
Publicado: (2023) -
Arterial indications for the low molecular weight heparins
por: Ageno, Walter, et al.
Publicado: (2001) -
Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000) -
Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
por: Locke, Charles FS, et al.
Publicado: (2005) -
Unfractionated and low molecular weight heparin
por: Lima, Marcelo, et al.
Publicado: (2014)